Diane Heiser
YOU?
Author Swipe
View article: Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias
Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias Open
The role of splicing dysregulation in cancer is underscored by splicing factor mutations; however, its impact in the absence of such rare mutations remains poorly understood. Prompted by the finding that splicing uniquely resolved genetic …
View article: Ex vivo discovery of synergistic drug combinations for hematologic malignancies
Ex vivo discovery of synergistic drug combinations for hematologic malignancies Open
Combination therapies have improved outcomes for patients with acute myeloid leukemia (AML). However, these patients still have poor overall survival. Although many combination therapies are identified with high-throughput screening (HTS),…
View article: Supplementary Table S2 from Role of <i>KEAP1</i>/<i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance
Supplementary Table S2 from Role of <i>KEAP1</i>/<i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance Open
Supplementary Table S2. Genotyping results for NSCLC patients treated with radiotherapy.
View article: Data from Role of <i>KEAP1</i>/<i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance
Data from Role of <i>KEAP1</i>/<i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance Open
Lung squamous cell carcinoma (LSCC) pathogenesis remains incompletely understood, and biomarkers predicting treatment response remain lacking. Here, we describe novel murine LSCC models driven by loss of Trp53 and Keap1, both of which are …
View article: Data from Role of <i>KEAP1</i>/<i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance
Data from Role of <i>KEAP1</i>/<i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance Open
Lung squamous cell carcinoma (LSCC) pathogenesis remains incompletely understood, and biomarkers predicting treatment response remain lacking. Here, we describe novel murine LSCC models driven by loss of Trp53 and Keap1, both of which are …
View article: Supplementary Methods, Figure Legends, Table Legends, Table S1, Tables S3 - S4 from Role of <i>KEAP1</i>/<i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance
Supplementary Methods, Figure Legends, Table Legends, Table S1, Tables S3 - S4 from Role of <i>KEAP1</i>/<i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance Open
Supplementary Table S1. In vivo limiting dilution analyses of P-LSCC and K/P-LSCC. Supplementary Table S3. Likely zygosity and functional effects of KEAP1 mutations in NSCLC patients in Fig. 7A. Supplementary Table S4. Clinical characteris…
View article: Supplementary Table S2 from Role of <i>KEAP1</i>/<i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance
Supplementary Table S2 from Role of <i>KEAP1</i>/<i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance Open
Supplementary Table S2. Genotyping results for NSCLC patients treated with radiotherapy.
View article: Supplementary Methods, Figure Legends, Table Legends, Table S1, Tables S3 - S4 from Role of <i>KEAP1</i>/<i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance
Supplementary Methods, Figure Legends, Table Legends, Table S1, Tables S3 - S4 from Role of <i>KEAP1</i>/<i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance Open
Supplementary Table S1. In vivo limiting dilution analyses of P-LSCC and K/P-LSCC. Supplementary Table S3. Likely zygosity and functional effects of KEAP1 mutations in NSCLC patients in Fig. 7A. Supplementary Table S4. Clinical characteris…
View article: Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms
Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms Open
Precision medicine approaches such as ex vivo drug sensitivity screening (DSS) are appealing to inform rational drug selection in myelodysplastic syndromes (MDSs) and acute myeloid leukemia, given their marked biologic heterogeneity. We ev…
View article: S133 EX VIVO DRUG SENSITIVITY PROFILING IN MYELODYSPLASTIC SYNDROME (MDS) PATIENTS DEFINES NOVEL DRUG SENSITIVITY PATTERNS FOR PREDICTING CLINICAL THERAPEUTIC OUTCOMES
S133 EX VIVO DRUG SENSITIVITY PROFILING IN MYELODYSPLASTIC SYNDROME (MDS) PATIENTS DEFINES NOVEL DRUG SENSITIVITY PATTERNS FOR PREDICTING CLINICAL THERAPEUTIC OUTCOMES Open
Background: Hypomethylating agents (HMAs) remain the standard of care for higher-risk MDS, but limited treatment options exist for patients with HMA-refractory MDS and related myeloid neoplasms. Aims: To demonstrate the clinical validity a…
View article: <i>Dnmt3a</i> deletion cooperates with the <i>Flt3/ITD</i> mutation to drive leukemogenesis in a murine model
<i>Dnmt3a</i> deletion cooperates with the <i>Flt3/ITD</i> mutation to drive leukemogenesis in a murine model Open
Internal tandem duplications of the juxtamembrane domain of FLT3 (FLT3/ITD) are among the most common mutations in Acute Myeloid Leukemia (AML). Resulting in constitutive activation of the kinase, FLT3/ITD portends a particularly poor prog…